A review of cognitive and behavioral outcomes of Brivaracetam
The Kaohsiung Journal of Medical Sciences · 2023-02 · 39 (2) · 104-114
DOI: 10.1002/kjm2.12648 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The Kaohsiung Journal of Medical Sciences, online erschienen am 20.01.2023. Verfasst von Kuan-Ying Li und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung, Taiwan. Hauptthemen laut MEDLINE: Anticonvulsants, Pyrrolidinones. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Health Research Institutes, Kaohsiung Medical University Research Center, Department of Neurology, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung, Taiwan.
Abstract (Originalsprache)
Anti‐seizure medications (ASMs) can cause cognitive or behavioral adverse drug reactions, which is an important consideration when selecting an appropriate ASM. Brivaracetam (BRV) is a newer synaptic vesicle protein 2A ligand, which is expected to result in fewer neuropsychiatric adverse effects due to its mechanism of action. To understand the impact of BRV on cognition and behavior compared with other ASMs, we conducted a review of the literature using the Cochrane Library, PubMed/MEDLINE, and Embase. After the screening process, a total of two animal studies, one randomized controlled trial, one pooled analysis of clinical trials, one controlled study, and nine observational studies were included. The animal studies showed that BRV did not worsen cognitive or behavioral performance in rodents. The human studies showed that BRV was associated with fewer cognitive adverse events compared with other second‐ or third‐generation ASMs. In addition, BRV was less associated with behavioral disturbance than levetiracetam. In summary, this review revealed that BRV has a limited impact on cognition and behavior. For patients who are intolerant to levetiracetam and have levetiracetam‐related behavioral side effects, switching to BRV could be beneficial. However, heterogeneity between studies resulted in low‐quality of evidence, and further trials are needed to confirm the findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung, Taiwan.
- Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
- Department of Neurology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
- Neuroscience Research Center, Kaohsiung Medical University, Kaohsiung, Taiwan.
- Department of Neurology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
- Department of and Master's Program in Neurology, Faculty of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
ORCID-Profile: Kuan-Ying Li, Chung-Yao Hsu, Yuan-Han Yang
Förderung
- National Health Research Institutes
- Kaohsiung Medical University Research Center
- Department of Neurology, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung, Taiwan
Zitieren
APA
Li, K. Y., Hsu, C. Y., & Yang, Y. H. (2023). A review of cognitive and behavioral outcomes of Brivaracetam. The Kaohsiung Journal of Medical Sciences, 39(2), 104-114. https://doi.org/10.1002/kjm2.12648
Vancouver
Li KY, Hsu CY, Yang YH. A review of cognitive and behavioral outcomes of Brivaracetam. The Kaohsiung Journal of Medical Sciences. 2023;39(2):104-114. doi:10.1002/kjm2.12648
BibTeX
@article{Li2023,
author = {Li, Kuan-Ying and Hsu, Chung-Yao and Yang, Yuan-Han},
title = {A review of cognitive and behavioral outcomes of Brivaracetam},
journal = {The Kaohsiung Journal of Medical Sciences},
year = {2023},
volume = {39},
number = {2},
pages = {104--114},
doi = {10.1002/kjm2.12648}
}
EUVIMED